BL Pharmtech Corp.

As of March 31, 2026, BL Pharmtech Corp. carries a market capitalization of 86.38B, placing it among publicly traded companies globally. Its enterprise value stands at 83.27B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, BL Pharmtech Corp. has 27.91M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 16.37, and the price-to-book ratio stands at 8.39.

These figures are as of March 31, 2026. The EV/Sales ratio of 16.54 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 83.27B versus a market cap of 86.38B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, BL Pharmtech Corp. maintains a current ratio of 1.23, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 34.09, indicating elevated leverage, while an interest coverage ratio of -2.17 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, BL Pharmtech Corp. posted a negative return on equity (ROE) of -91.07, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -54.13, reflecting losses generated across the asset base. The company generates approximately 387.36M in revenue per employee across its workforce of 13.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.51 indicates how many times BL Pharmtech Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, BL Pharmtech Corp. recorded 18.28M in income tax expense. The company reported a pretax loss of -15.18B and -15.19B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, BL Pharmtech Corp.'s stock has gained approximately 182.89% over the past 52 weeks. The 50-day moving average sits at 2,171.44, while the 200-day moving average is 2,491.56.

Over the twelve months ended March 31, 2026, BL Pharmtech Corp. generated 5.04B in revenue and converted that into -15.19B in net income, yielding earnings per share of -570.72. EBITDA reached -1.68B, while operating income came in at 1.62B.

As of March 31, 2026, BL Pharmtech Corp. holds 6.65B in cash and equivalents against 3.52B in total debt, resulting in a net debt position of -3.60B. Total book value stands at 10.30B, with working capital of 1.64B providing operational flexibility.

BL Pharmtech Corp. produced -2.48B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -5.70M in capital expenditures, free cash flow totaled -2.49B - equivalent to -93.35 per share.

Over the twelve months ended March 31, 2026, BL Pharmtech Corp. posted a gross margin of 57.66, reflecting its pricing power and cost economics. The operating margin of 32.09 and net profit margin of -301.63 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -3.02: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 3.52, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to BL Pharmtech Corp. shareholders.

BL Pharmtech Corp.'s most recent stock split took place on February 26, 2025 with a 1:3 split ratio.

As of March 31, 2026, BL Pharmtech Corp. has an Altman Z-Score of -0.65, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.